Skip to main content

FDA Clears Newest Version of Celera's HIV-1 Genotyping Software

NEW YORK (GenomeWeb News) – Celera said today that the US Food and Drug Administration has granted marketing clearance for the firm’s ViroSeq HIV-1 Genotyping System Software v2.8.
 
The Alameda, Calif.-based firm’s HIV-1 Genotyping System detects mutations in the HIV-1 viral genome that confer resistance. It is used by physicians in monitoring and treating HIV-1 infections.
 
The newest version of the software includes the resistance algorithm for two new anti-HIV drugs, Intelence (etravirine) and Prezista (darunavir). It also includes an update of the resistance algorithm for all currently available protease and reverse transcriptase inhibitors, said Celera.
 
The ViroSeq system is manufactured by Celera and distributed by Abbott Laboratories.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.